- Home
- ATHA vs MIRA Comparison
ATHA vs MIRA Comparison
Compare ATHA & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- MIRA
- Stock Information
- Founded
- ATHA 2011
- MIRA 2020
- Country
- ATHA United States
- MIRA United States
- Employees
- ATHA N/A
- MIRA N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- ATHA Health Care
- MIRA Health Care
- Exchange
- ATHA Nasdaq
- MIRA Nasdaq
- Market Cap
- ATHA 21.0M
- MIRA 20.5M
- IPO Year
- ATHA 2020
- MIRA 2023
- Fundamental
- Price
- ATHA $0.26
- MIRA $1.19
- Analyst Decision
- ATHA Buy
- MIRA Strong Buy
- Analyst Count
- ATHA 4
- MIRA 2
- Target Price
- ATHA $11.25
- MIRA $14.00
- AVG Volume (30 Days)
- ATHA 204.2K
- MIRA 3.4M
- Earning Date
- ATHA 05-14-2025
- MIRA 05-20-2025
- Dividend Yield
- ATHA N/A
- MIRA N/A
- EPS Growth
- ATHA N/A
- MIRA N/A
- EPS
- ATHA N/A
- MIRA N/A
- Revenue
- ATHA N/A
- MIRA N/A
- Revenue This Year
- ATHA N/A
- MIRA N/A
- Revenue Next Year
- ATHA N/A
- MIRA N/A
- P/E Ratio
- ATHA N/A
- MIRA N/A
- Revenue Growth
- ATHA N/A
- MIRA N/A
- 52 Week Low
- ATHA $0.22
- MIRA $0.51
- 52 Week High
- ATHA $3.67
- MIRA $5.01
- Technical
- Relative Strength Index (RSI)
- ATHA 42.81
- MIRA 58.22
- Support Level
- ATHA $0.23
- MIRA $1.03
- Resistance Level
- ATHA $0.27
- MIRA $1.30
- Average True Range (ATR)
- ATHA 0.03
- MIRA 0.11
- MACD
- ATHA 0.00
- MIRA 0.02
- Stochastic Oscillator
- ATHA 27.53
- MIRA 72.83
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.